WOCKPHARMA - Swing Trade Analysis with AI Signals
Back to ListSwing Trade Rating: 4.3
| Stock Code | WOCKPHARMA | Market Cap | 32,324 Cr. | Current Price | 1,989 ₹ | High / Low | 2,422 ₹ |
| Stock P/E | 111 | Book Value | 190 ₹ | Dividend Yield | 0.00 % | ROCE | 9.74 % |
| ROE | 9.99 % | Face Value | 5.00 ₹ | DMA 50 | 1,698 ₹ | DMA 200 | 1,484 ₹ |
| Chg in FII Hold | 0.09 % | Chg in DII Hold | 0.41 % | PAT Qtr | 132 Cr. | PAT Prev Qtr | 38.0 Cr. |
| RSI | 61.0 | MACD | 96.6 | Volume | 32,28,077 | Avg Vol 1Wk | 20,00,004 |
| Low price | 1,087 ₹ | High price | 2,422 ₹ | PEG Ratio | 2.29 | Debt to equity | 0.64 |
| 52w Index | 67.6 % | Qtr Profit Var | 230 % | EPS | 19.5 ₹ | Industry PE | 32.1 |
📊 WOCKPHARMA shows strong technical momentum supported by earnings growth and institutional confidence, though valuations remain stretched. The RSI at 61.0 indicates healthy bullish momentum, while the MACD at 96.6 confirms strong upward trend. Current price (1,989 ₹) is above both the 50DMA (1,698 ₹) and 200DMA (1,484 ₹), reflecting sustained strength. ROCE (9.74%) and ROE (9.99%) are moderate, but quarterly PAT surged (132 Cr. vs 38 Cr.), showing robust earnings momentum. P/E of 111 vs industry average of 32.1 highlights overvaluation risk.
💡 Optimal Entry Price: Around 1,900–1,950 ₹ (near support zone close to DMA levels).
📈 Exit Strategy if Holding: Consider booking profits near 2,350–2,400 ₹ resistance zone, or trail stop-loss below 1,850 ₹.
Positive
- ✅ Quarterly PAT growth (+230%) shows strong earnings momentum.
- ✅ EPS of 19.5 ₹ supports valuation strength.
- ✅ Price above both 50DMA and 200DMA confirms bullish trend.
- ✅ FII (+0.09%) and DII (+0.41%) inflows show institutional confidence.
- ✅ Strong trading volume (32.3 lakh vs avg 20 lakh) indicates active participation.
Limitation
- ⚠️ Very high P/E ratio (111 vs industry 32.1) suggests overvaluation.
- ⚠️ Dividend yield of 0.00% offers no income support.
- ⚠️ Debt-to-equity ratio of 0.64 is relatively high.
- ⚠️ ROCE and ROE remain moderate compared to peers.
Company Negative News
- 📉 No major external negative news, but high valuation and debt levels remain concerns.
Company Positive News
- 📈 Quarterly profits surged significantly (+230%).
- 📈 Institutional investors increased holdings (FII and DII).
- 📈 Technical indicators (MACD strong, RSI bullish) support short-term strength.
Industry
- 🏭 Industry P/E at 32.1 shows sector trading at moderate multiples.
- 🏭 Pharma sector outlook remains stable with steady demand.
Conclusion
🔎 WOCKPHARMA is technically strong and supported by earnings growth and institutional buying, making it a good candidate for swing trading. Entry near 1,900–1,950 ₹ offers a favorable setup, with profit booking advised around 2,350–2,400 ₹. Traders should remain cautious due to high valuation, debt levels, and moderate efficiency metrics.
Would you like me to expand this into a peer benchmarking overlay comparing WOCKPHARMA with Sun Pharma and Cipla, or a sector overlay against the broader pharmaceutical industry for deeper context?